ArticleThe Journal of experimental medicine2020

Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.

Atsushi Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.